Merck & Co., Inc.

BRSE:010683053 Stock Report

Market Cap: CHF 222.0b

Merck Valuation

Is 010683053 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 010683053 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 010683053 (CHF87.45) is trading below our estimate of fair value (CHF275.72)

Significantly Below Fair Value: 010683053 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 010683053?

Key metric: As 010683053 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 010683053. This is calculated by dividing 010683053's market cap by their current earnings.
What is 010683053's PE Ratio?
PE Ratio20.5x
EarningsUS$12.15b
Market CapUS$249.17b

Price to Earnings Ratio vs Peers

How does 010683053's PE Ratio compare to its peers?

The above table shows the PE ratio for 010683053 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average23.5x
ROG Roche Holding
19.6x11.1%CHF 210.3b
NOVN Novartis
17.7x7.0%CHF 185.4b
DESN Dottikon ES Holding
40.9xn/aCHF 3.3b
COPN Cosmo Pharmaceuticals
15.9x17.2%CHF 1.0b
010683053 Merck
20.5x15.5%CHF 249.2b

Price-To-Earnings vs Peers: 010683053 is good value based on its Price-To-Earnings Ratio (20.5x) compared to the peer average (23.5x).

Price to Earnings Ratio vs Industry

How does 010683053's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
010683053 20.5xIndustry Avg. 21.2xNo. of Companies7PE01224364860+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 010683053 is good value based on its Price-To-Earnings Ratio (20.5x) compared to the European Pharmaceuticals industry average (21.2x).

Price to Earnings Ratio vs Fair Ratio

What is 010683053's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

010683053 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio20.5x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 010683053's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 010683053 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 87.45
CHF 117.36
+34.2%
9.3%CHF 138.11CHF 89.10n/a27
Nov ’25CHF 90.05
CHF 116.28
+29.1%
7.9%CHF 134.94CHF 95.77n/a27
Oct ’25CHF 96.18
CHF 118.05
+22.7%
5.8%CHF 131.61CHF 101.89n/a26
Sep ’25CHF 98.27
CHF 118.36
+20.4%
5.9%CHF 131.78CHF 102.03n/a26
Aug ’25CHF 101.21
CHF 123.30
+21.8%
5.5%CHF 135.41CHF 104.83n/a26
Jul ’25CHF 116.13
CHF 127.45
+9.8%
5.3%CHF 138.46CHF 107.19n/a25
Jun ’25CHF 113.07
CHF 129.40
+14.4%
6.1%CHF 141.37CHF 107.62n/a25
May ’25CHF 119.66
CHF 130.10
+8.7%
6.1%CHF 142.47CHF 108.46n/a26
Apr ’25n/a
CHF 123.23
0%
5.7%CHF 133.90CHF 103.14n/a25
Mar ’25CHF 112.90
CHF 117.79
+4.3%
7.6%CHF 130.44CHF 90.78n/a26
Feb ’25CHF 104.59
CHF 109.56
+4.8%
7.6%CHF 120.08CHF 88.34n/a27
Jan ’25n/a
CHF 106.60
0%
7.0%CHF 117.09CHF 89.33n/a28
Dec ’24n/a
CHF 108.03
0%
6.8%CHF 117.98CHF 90.02n/a28
Nov ’24n/a
CHF 111.54
0%
6.6%CHF 121.71CHF 92.86CHF 90.0527
Oct ’24n/a
CHF 110.24
0%
6.8%CHF 121.17CHF 92.45CHF 96.1827
Sep ’24CHF 97.32
CHF 108.44
+11.4%
7.2%CHF 119.29CHF 85.72CHF 98.2728
Aug ’24CHF 91.65
CHF 107.89
+17.7%
7.0%CHF 118.16CHF 84.90CHF 101.2128
Jul ’24n/a
CHF 109.92
0%
8.0%CHF 121.07CHF 86.99CHF 116.1326
Jun ’24n/a
CHF 111.21
0%
8.3%CHF 123.08CHF 87.78CHF 113.0727
May ’24n/a
CHF 110.30
0%
9.6%CHF 138.91CHF 86.93CHF 119.6628
Apr ’24n/a
CHF 110.36
0%
10.9%CHF 142.46CHF 88.23n/a27
Mar ’24CHF 103.42
CHF 111.85
+8.2%
10.8%CHF 144.66CHF 89.60CHF 112.9026
Feb ’24n/a
CHF 107.64
0%
9.3%CHF 124.50CHF 88.80CHF 104.5924
Jan ’24CHF 104.33
CHF 105.81
+1.4%
9.5%CHF 126.37CHF 90.13n/a24
Dec ’23n/a
CHF 103.25
0%
6.9%CHF 117.75CHF 91.37n/a23
Nov ’23CHF 100.61
CHF 105.60
+5.0%
9.1%CHF 125.17CHF 85.11n/a22

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Roche Holding

CHF 210.3b

Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania.

RO

CHF 279.20

7D

-2.7%

1Y

10.9%

Roche Holding

CHF 210.3b

Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania.

ROG

CHF 261.60

7D

-1.6%

1Y

10.4%

Evotec

€1.5b

Operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide.

EVT

€27.76

7D

0%

1Y

0%